(Q33545121)

27 July 2017

1 reference

title

Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events (English)

1 reference

27 July 2017

Sacks FM

1

1 reference

27 July 2017

Ridker PM

series ordinal

2

1 reference

27 July 2017

publication date

1 February 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

24

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

51-56

1 reference

Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03043818

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03043818

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03043818

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03043818

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

21 January 2018

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1 reference

12 December 2020

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

1 reference

12 December 2020

Statins do more than just lower cholesterol

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

12 December 2020

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03043818

1 reference

27 July 2017

1 reference